Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Conditions: Hematologic Malignancy; Bone Marrow Transplant Rejection; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); Acute Lymphoblastic Leukemia (ALL), Adult; Multiple Myeloma; Aplastic Anemia; Lymphoma; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Chronic Myeloid Leukemia; Myelofibrosis Interventions: Drug: Darzalex Faspro (Daratumumab and hyaluronidase-fihj); Device: JH-DSA Semi-Quant Screen and Response Score Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Janssen Research& Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Anemia | Aplastic Anemia | Bone Marrow Transplant | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Non-Hodgkin's Lymphoma | Research | Stem Cell Therapy | Stem Cells | Transplants